Correct. For Barron’s to write a couple of paragraphs about SNY’s valuation without even mentioning the possibility of Lovenox going generic in its largest market is tantamount to gross negligence, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”